Lexeo Therapeutics, Inc. Common Stock
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $68,513,000.
Profit Margin
| 2020 | 518.47K | -5.15M | -993.83% |
|---|---|---|---|
| 2021 | 1.65M | -50.62M | -3055.04% |
| 2022 | 654K | -59.27M | -9063.76% |
| 2023 | 0 | -66.39M |
LXEO Income Statement (2020 – 2023)
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
Revenue | ||||
Revenue | 0 | 654K | 1.65M | 518.47K |
Cost of revenue | 1.84M | 0 | 0 | 0 |
Gross profit | -1.84M | 654K | 1.65M | 518.47K |
Operating exp. | ||||
Research and development | 53.13M | 49.16M | 45.12M | 4.31M |
Selling and marketing | -1.84M | 0 | 0 | 0 |
Total operating expenses | 68.51M | 61.16M | 52.29M | 5.10M |
Operating income | -68.51M | -60.50M | -50.63M | -4.58M |
Other income (expenses), net | 2.11M | -2K | -155 | -565K |
Income before tax | -66.39M | -59.27M | -50.62M | -5.15M |
Income tax expense | 0 | 89K | -155 | 147.15K |
Net income | -66.39M | -59.27M | -50.62M | -5.15M |
Earnings per share | ||||
Basic EPS | -2.49 | -2.4 | -2.05 | -0.21 |
Diluted EPS | -2.49 | -2.4 | -2.05 | -0.21 |
| Data source |